Citation

Shi Y, Wang Y, Meng W, Brigance RP, Ryono DE, Bolton S, Zhang H, Chen S, Smirk R, Tao S, Tino JA, Williams KN, Sulsky R, Nielsen L, Ellsworth B, Wong MKY, Sun JH, Leith LW, Sun D, Wu DR, Gupta A, Rampulla R, Mathur A, Chen BC, Wang A, Fuentes-Catanio HG, Kunselman L, Cap M, Zalaznick J, Ma X, Liu H, Taylor JR, Zebo R, Jones B, Kalinowski S, Swartz J, Staal A, O'Malley K, Kopcho L, Muckelbauer JK, Krystek SR, Spronk SA, Marcinkeviciene J, Everlof G, Chen XQ, Xu C, Li YX, Langish RA, Yang Y, Wang Q, Behnia K, Fura A, Janovitz EB, Pannacciulli N, Griffen S, Zinker BA, Krupinski J, Kirby M, Whaley J, Zahler R, Barrish JC, Robl JA, Cheng PTW.: Discovery of a Partial Glucokinase Activator Clinical Candidate: Diethyl ((3-(3-((5-(Azetidine-1-carbonyl)pyrazin-2-yl)oxy)-5-isopropoxybenzamido)-1<i>H</i>-pyrazol-1-yl)methyl)phosphonate (BMS-820132). J Med Chem, Volume 65 (5), 2022

Authors

Barrish JC, Behnia K, Bolton S, Brigance RP, Cap M, Chen BC, Chen S, Chen XQ, Cheng PTW., Ellsworth B, Everlof G, Fuentes-Catanio HG, Fura A, Griffen S, Gupta A, Janovitz EB, Jones B, Kalinowski S, Kirby M, Kopcho L, Krupinski J, Krystek SR, Kunselman L, Langish RA, Leith LW, Li YX, Liu H, Ma X, Marcinkeviciene J, Mathur A, Meng W, Muckelbauer JK, Nielsen L, O'Malley K, Pannacciulli N, Rampulla R, Robl JA, Ryono DE, Shi Y, Smirk R, Spronk SA, Staal A, Sulsky R, Sun D, Sun JH, Swartz J, Tao S, Taylor JR, Tino JA, Wang A, Wang Q, Wang Y, Whaley J, Williams KN, Wong MKY, Wu DR, Xu C, Yang Y, Zahler R, Zalaznick J, Zebo R, Zhang H, Zinker BA

Journal

J Med Chem

Year

2022

DOI

10.1021/acs.jmedchem.1c02110

PubMed

35179904

Machine-readable

REST APIRDF